Your browser is no longer supported. Please, upgrade your browser.
Settings
SRRA [NASD]
Sierra Oncology, Inc.
Index- P/E- EPS (ttm)-7.75 Insider Own6.35% Shs Outstand11.03M Perf Week1.99%
Market Cap215.16M Forward P/E- EPS next Y-4.89 Insider Trans0.00% Shs Float10.23M Perf Month-3.19%
Income-80.90M PEG- EPS next Q-1.60 Inst Own78.20% Short Float0.07% Perf Quarter12.41%
Sales0.30M P/S717.20 EPS this Y74.60% Inst Trans8.34% Short Ratio0.21 Perf Half Y49.35%
Book/sh8.88 P/B2.02 EPS next Y20.90% ROA-67.00% Target Price27.75 Perf Year60.81%
Cash/sh8.67 P/C2.07 EPS next 5Y- ROE-72.00% 52W Range10.02 - 20.43 Perf YTD11.85%
Dividend- P/FCF- EPS past 5Y- ROI-66.40% 52W High-12.24% Beta1.07
Dividend %- Quick Ratio11.40 Sales past 5Y- Gross Margin- 52W Low78.94% ATR0.92
Employees69 Current Ratio11.40 Sales Q/Q- Oper. Margin- RSI (14)53.23 Volatility3.83% 5.32%
OptionableNo Debt/Eq0.00 EPS Q/Q79.10% Profit Margin- Rel Volume0.51 Prev Close18.40
ShortableYes LT Debt/Eq0.00 EarningsMar 11 BMO Payout- Avg Volume34.81K Price17.93
Recom1.50 SMA20-0.96% SMA509.83% SMA20027.65% Volume17,592 Change-2.55%
Dec-11-20Resumed H.C. Wainwright Buy $29
Jul-30-20Initiated H.C. Wainwright Buy $20
Dec-06-19Initiated Oppenheimer Outperform $1.20
Oct-23-17Upgrade Jefferies Hold → Buy
Mar-10-17Upgrade SunTrust Hold → Buy
Feb-22-17Resumed Wedbush Outperform $3 → $4
Mar-23-21 07:00AM  
07:00AM  
Mar-12-21 04:16AM  
Mar-11-21 07:00AM  
07:00AM  
Mar-05-21 08:00AM  
Mar-03-21 07:00AM  
07:00AM  
Feb-12-21 07:00AM  
07:00AM  
Feb-09-21 07:00AM  
Jan-18-21 08:11AM  
Jan-05-21 07:00AM  
07:00AM  
Dec-15-20 04:27PM  
Dec-11-20 06:49PM  
Dec-07-20 10:00AM  
Dec-05-20 10:30AM  
10:30AM  
Dec-01-20 07:00AM  
07:00AM  
Nov-25-20 07:00AM  
Nov-18-20 02:33AM  
Nov-12-20 07:00AM  
Nov-05-20 08:00AM  
08:00AM  
07:00AM  
Oct-02-20 07:00AM  
07:00AM  
Sep-14-20 07:00AM  
07:00AM  
Sep-04-20 03:47PM  
Aug-06-20 07:05AM  
07:00AM  
Jul-28-20 07:00AM  
Jun-26-20 11:44AM  
Jun-18-20 12:00PM  
Jun-16-20 04:05PM  
Jun-12-20 02:30AM  
02:30AM  
May-27-20 07:00AM  
07:00AM  
May-26-20 07:00AM  
07:00AM  
May-14-20 09:00AM  
May-07-20 08:00AM  
08:00AM  
07:00AM  
May-04-20 12:45PM  
Apr-21-20 05:31PM  
Mar-03-20 07:00AM  
Feb-26-20 08:47AM  
07:00AM  
Feb-25-20 07:00AM  
Feb-11-20 07:23AM  
Feb-06-20 07:00AM  
Jan-28-20 07:09AM  
Jan-22-20 07:00AM  
Jan-06-20 02:17PM  
Dec-19-19 06:08PM  
Dec-07-19 09:00AM  
09:00AM  
Dec-02-19 07:00AM  
Nov-26-19 07:00AM  
Nov-20-19 07:00AM  
Nov-14-19 04:05PM  
04:05PM  
Nov-07-19 09:02AM  
09:01AM  
09:01AM  
Nov-06-19 04:01PM  
04:01PM  
09:00AM  
Nov-04-19 04:01PM  
04:01PM  
Sep-13-19 12:00PM  
Aug-08-19 07:00AM  
Aug-07-19 07:00AM  
Jul-15-19 03:03PM  
Jun-29-19 11:33PM  
Jun-27-19 07:00AM  
07:00AM  
Jun-05-19 06:00AM  
06:00AM  
Jun-04-19 05:04PM  
05:04PM  
Jun-03-19 07:00AM  
07:00AM  
Jun-01-19 09:00AM  
May-28-19 07:00AM  
07:00AM  
May-15-19 05:00PM  
May-08-19 07:53AM  
07:00AM  
07:00AM  
May-06-19 07:00AM  
Apr-26-19 11:55AM  
Apr-03-19 08:00AM  
Apr-01-19 04:05PM  
04:05PM  
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klencke BarbaraChief Development OfficerAug 18Buy12.253,32540,7385,000Aug 18 08:16 PM
Klencke BarbaraChief Development OfficerAug 18Buy12.225,95072,71010,000Aug 18 08:16 PM